Purdue University, USA Dr Jin Li has over 30 years biopharmaceutical experience (at Protherics and AstraZeneca), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Before founding HitGen, he held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca. This included responsibility for computational chemistry, computational biology and compound collection enhancement. Dr Li completed his BSc at Sichuan University, and PhD in macromolecular sciences at Aston University. He then completed post-doctoral research in theoretical biochemistry at Manchester University, UK. Dr Li is also a Fellow of the Royal Society of Chemistry.

• Overview of Affinity-based DEL Selections with Select Target Types and AchievementsMachine Learning with DEL Selection Data and for DEL designOne bead one compound (OBOC) DELs for Biochemical ScreensLive cell-based DEL SelectionsOn-DNA Medicinal Chemistry: Focused libraries, fragment expansion, and hit optimizationDELs with Covalent WarheadsApplication of DELs for E3 Ligase Ligand and PROTAC development

Purdue University, USA Dr Jin Li has over 30 years biopharmaceutical experience (at Protherics and AstraZeneca), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Before founding HitGen, he held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca. This included responsibility for computational chemistry, computational biology and compound collection enhancement. Dr Li completed his BSc at Sichuan University, and PhD in macromolecular sciences at Aston University. He then completed post-doctoral research in theoretical biochemistry at Manchester University, UK. Dr Li is also a Fellow of the Royal Society of Chemistry.

• Overview of Affinity-based DEL Selections with Select Target Types and AchievementsMachine Learning with DEL Selection Data and for DEL designOne bead one compound (OBOC) DELs for Biochemical ScreensLive cell-based DEL SelectionsOn-DNA Medicinal Chemistry: Focused libraries, fragment expansion, and hit optimizationDELs with Covalent WarheadsApplication of DELs for E3 Ligase Ligand and PROTAC development

Purdue University, USA Dr Jin Li has over 30 years biopharmaceutical experience (at Protherics and AstraZeneca), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Before founding HitGen, he held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca. This included responsibility for computational chemistry, computational biology and compound collection enhancement. Dr Li completed his BSc at Sichuan University, and PhD in macromolecular sciences at Aston University. He then completed post-doctoral research in theoretical biochemistry at Manchester University, UK. Dr Li is also a Fellow of the Royal Society of Chemistry.

• Overview of Affinity-based DEL Selections with Select Target Types and AchievementsMachine Learning with DEL Selection Data and for DEL designOne bead one compound (OBOC) DELs for Biochemical ScreensLive cell-based DEL SelectionsOn-DNA Medicinal Chemistry: Focused libraries, fragment expansion, and hit optimizationDELs with Covalent WarheadsApplication of DELs for E3 Ligase Ligand and PROTAC development